Products
Trontinemab Biosimilar Bispecific Antibody (Amyloid Beta × Transferrin Receptor 1) for Research
Cat No.: GMP-Bios-INN-1428
Anti-APP Abeta 1-40/42 therapeutic antibody (Pre-made Trontinemab biosimilar,Bispecific Mixed Format with Domain Crossover) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Trontinemab (development codes RG-6102/RO 7126209) is a humanized bispecific antibody targeting amyloid precursor protein (APP) and transferrin receptor 1 (TFRC). It is developed by Roche for Dementia in Phase II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1428-1mg | 1mg | |
| GMP-Bios-INN-1428-10mg | 10mg | |
| GMP-Bios-INN-1428-100mg | 100mg | |
| GMP-Bios-INN-1428-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Trontinemab biosimilar, Bispecific Mixed Format with Domain Crossover, Anti-APP Abeta 1-40/42;TFRC/CD71 Antibody: Anti-CD71/TFRC/Transferrin receptor protein 1/TR therapeutic antibody |
| INN Name | Trontinemab |
| Target | APP Abeta 1-40/42;TFRC/CD71 |
| Format | Bispecific Mixed Format with Domain Crossover |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1;G1 |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | 5csz:AB:HL;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2022 |
| Year Recommended | 2022 |
| Companies | Roche |
| Conditions Approved | na |
| Conditions Active | Dementia |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
